Physicians: maximum of 0.5 AMA PRA Category 1 Credits™
Registered Nurses: 0.5 Nursing contact hours
Released: August 26, 2021 Expiration: August 25, 2022
Upon completion of this activity, participants should be able to:
- Adopt best practices in recognizing and managing comorbidities in patients with MS
- Discuss the influence of comorbidities on MS treatment outcomes
This program is intended for neurologists, primary care physicians, nurse practitioners, nurses, and other healthcare providers who care for patients with MS.
The goal of this activity is to improve the knowledge and competence of learners to recognize and manage comorbidities and MS symptoms in patients with MS.
Patricia K. Coyle, MD, FAAN, FANA
Professor and Vice Chair (Clinical Affairs)
Director, MS Comprehensive Care Center
Department of Neurology
Stony Brook University Hospital
Stony Brook, New York
Patricia Melville, ANP-BC, MSCN
Neurology/MS Comprehensive Care Center
Stony Brook University Medical Center
Stony Brook, New York
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Consortium of Multiple Sclerosis Centers (CMSC) and Clinical Care Options, LLC. CMSC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
The Consortium of Multiple Sclerosis Centers designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Education
The Consortium of Multiple Sclerosis Centers designates this enduring material for 0.5 contact hours of nursing continuing professional development.
Information on this Educational Activity
In accordance with the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Continuing Education, CMSC require that individuals in a position to control the content of an educational activity disclose all financial relationships with ineligible companies. CMSC mitigate all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, CMSC seek to verify that all scientific research referred to, reported, or used in a CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. CMSC is committed to providing learners with high-quality CE activities that promote improvements in health care and not those of a commercial interest.
The program faculty reported the following relevant financial relationships that they have with ineligible companies:
Patricia K. Coyle, MD, FAAN, FANA, has disclosed that she has received consulting fees from Accordant, Alexion, Bayer, Biogen, Bristol-Myers Squibb, Celgene, EMD Serono, Genentech/Roche, GlaxoSmithKline, Janssen, Mylan, Novartis, Sanofi Genzyme, TG Therapeutics, and Viela Bio; funds for research support from Alkermes, Corrona, Genentech/Roche, MedDay, and NINDS; and fees for non-CME/CE services from Biogen and Janssen.
Patricia Melville, ANP-BC, MSCN, has disclosed that she has received consulting fees from Alexion, Biogen, Celgene/Bristol-Myers Squibb, Genentech, and Sanofi Genzyme and fees for non-CME/CE services from Alexion, Biogen, Celgene/Bristol-Myers Squibb, Genentech, Novartis, and Sanofi Genzyme.
The planners, content developers, reviewers, and other staff at Clinical Care Options, LLC have disclosed no relevant financial relationships.
All of the relevant financial relationships listed for these individuals have been mitigated.
Disclosure of Unlabeled Use
CMSC require faculty to disclose to the attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved); and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.
CMSC present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. CMSC and the commercial supporter(s) assume no liability for the information herein.